There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
BPL-003 Efficacy and Safety in Treatment Resistant Depression
NCT05870540
Recruiting
This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: UAB School of Public Health, Department of Health Behavior, Birmingham, Alabama
Conditions: Treatment Resistant Depression
Register for Updates
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Local Institution - 0006, Birmingham, Alabama +1 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Register for Updates
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
NCT06173323
Recruiting
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Heal... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Shena Gazaway, Birmingham, Alabama
Conditions: Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Register for Updates
INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963
Recruiting
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/29/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Intracranial Aneurysm
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
05/29/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793
Recruiting
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Liposarcoma, Dedifferentiated
Register for Updates
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290
Recruiting
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Register for Updates
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646
Recruiting
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2024
Locations: Central Research Associates LLC dba Flourish Research, Birmingham, Alabama +1 locations
Conditions: Endometriosis
Register for Updates
An Optimization Pilot to Optimize An Early Palliative Care Intervention for Advanced Heart Failure
NCT05879887
Recruiting
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this randomized factorial pilot trial is to identify feasibility, acceptability, and preliminary efficacy of components of an intervention (UPHOLDS) to improve quality of life of older adults with advanced heart failure. Using a 2x2x2x2 factorial design, 64 adults with advanced heart failure will be randomized to receive one or more palliative care coach-delivered components, based on Ferrans' Heal... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
05/29/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Chronic Illness
Register for Updates
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: The University of Alabama At Birmingham, Birmingham, Alabama
Conditions: Pulmonary Embolism
Register for Updates
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288
Recruiting
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/29/2024
Locations: Local Institution - 0042, Birmingham, Alabama
Conditions: Renal Allograft Recipients
Register for Updates
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
NCT05516498
Recruiting
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/29/2024
Locations: Research Site, Birmingham, Alabama
Conditions: Liver Cirrhosis
Register for Updates